Publications by authors named "S K Shapira"
Background: In the complex landscape of modern warfare, understanding combat-related injuries leading to hospitalization is crucial for optimizing injury treatment. This study aims to compare combat casualty characteristics and outcomes during the major conflicts between Israel and Hamas in 2023 and 2014 as a basis for understanding the effectiveness of trauma care practices for wounded soldiers.
Methods: A cohort study of soldiers hospitalized due to combat injuries during two major wars between Israel and Hamas in 2023 and 2014, using data from the Israeli National Trauma Registry.
Article Synopsis
- Combat casualty care has improved due to evidence-based protocols, with a study comparing prehospital care and outcomes of patients from conflicts in 2014 and 2023 in southern Israel.
- The study found that the number of evacuated patients increased significantly from 251 in 2014 to 940 in 2023, while the time to hospital arrival decreased.
- There was an increase in the proportion of severely injured patients, a decrease in some advanced prehospital interventions, and an increase in prehospital blood transfusions, but in-hospital mortality rates remained stable across both conflicts.
Objectives: Asciminib, a novel allosteric BCR::ABL1 inhibitor, targets the ABL1 myristoyl pocket to potentially reduce toxicity and enhance efficacy. It is approved for Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia (CML-CP) in patients with resistance or intolerance to two or more tyrosine kinase inhibitors (TKIs) or those with the T315I mutation.
Methods: This retrospective analysis evaluated patients with CML treated with asciminib under a managed-access program across eight Israeli centers from July 2019 to August 2022.
Article Synopsis
- * In the phase 2 trial, 20 patients received anti-CD19 CAR-T therapy combined with nivolumab, which was found to be safe; results showed an impressive 84% overall response rate and notable progression-free and overall survival rates at both 6 and 12 months.
- * Although CAR-T cell expansion was similar in patients eligible and ineligible for nivolumab, those eligible had a higher proportion of specific beneficial immune cell types, indicating that further
Introduction: In recent years, fedratinib, a selective JAK2 inhibitor, has emerged as a potential therapeutic option for patients who have failed or are intolerant to ruxolitinib. Despite the promising results observed in clinical studies, real-world evidence from the USA and Europe suggests that the efficacy of fedratinib may be less conclusive. We report the characteristics, treatment patterns, and clinical outcomes of patients with myelofibrosis (MF) treated with fedratinib following ruxolitinib failure in Israel's clinical practice.
View Article and Find Full Text PDF